STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors.
Pinto N, Albert CM, Taylor MR, Ullom HB, Wilson AL, Huang W, Wendler J, Pattabhi S, Seidel K, Brown C, Gustafson JA, Rawlings-Rhea SD, Cheeney SHE, Burleigh K, Gustafson HH, Orentas RJ, Vitanza NA, Gardner RA, Jensen MC, Park JR.
Pinto N, et al. Among authors: cheeney she.
J Clin Oncol. 2024 Sep 10:JCO2302229. doi: 10.1200/JCO.23.02229. Online ahead of print.
J Clin Oncol. 2024.
PMID: 39255444